Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Industry

XORTX Therapeutics warns of going-concern doubt as cash falls to $318,846

The gout and kidney disease developer reports a nine-month net loss of about $2.88M, after a share consolidation and a voluntary TSX Venture delisting.

16 Nov 2026 · XORTX Therapeutics Inc. XRTX · Company news

XORTX Therapeutics, a late-stage company developing therapies for gout and kidney disease, has filed unaudited interim financial statements for the nine months ended 30 September 2026. The statements show a net loss of about $2.88M and cash of $318,846.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): XORTX Therapeutics Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More IndustryAll →